文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

COVID-19大流行期间美国远程医疗使用与阿片类使用障碍治疗质量

Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
PubMed 文献 · JAMA Netw Open · 2023-01-03
一句话结论高远程医疗使用与低使用组患者的阿片类使用障碍临床结局相似,远程医疗是面对面照护的可比替代方案,但未增加治疗可及性。

该队列研究利用OptumLabs数据仓库的去标识化行政索赔数据,纳入11801例阿片类使用障碍(OUD)患者(平均[SD]年龄53.9[15.7]岁;男性5902例[50.0%]),由1768名临床医生治疗,按远程医疗使用比例分为低、中、高三组。大流行期间高使用组平均69.5%(18.6%)的办公室访视以虚拟方式进行,低使用组仅2.1%(2.5%)。比较大流行前后,高 vs 低远程医疗使用组在OUD药物(MOUD)启动(调整OR 1.00;95%CI 0.84-1.19)、MOUD供应天数(差异变化-0.27天;95%CI -1.84至1.30)及OUD相关临床事件(调整OR 1.01;95%CI 0.73-1.24)方面无差异变化。结论提示远程医疗与面对面OUD照护的临床结局相似,但无证据表明远程医疗增加治疗可及性或改善质量。

要点

  • 高远程医疗使用组大流行期间平均69.5%(18.6%)的办公室访视以虚拟方式进行,低使用组仅2.1%(2.5%)。
  • 高 vs 低远程医疗使用组患者MOUD启动的调整OR为1.00(95%CI 0.84-1.19),无差异变化。
  • 高 vs 低远程医疗使用组MOUD供应天数差异变化为-0.27天(95%CI -1.84至1.30),无差异变化。
  • 高 vs 低远程医疗使用组OUD相关临床事件(药物过量、住院脱毒/康复中心停留或注射吸毒相关感染)调整OR为1.01(95%CI 0.73-1.24),无差异变化。
  • 高(2.6至2.7次/患者发作)与低(3.1至3.3次/患者发作)远程医疗使用组的总OUD访视量(面对面加远程医疗)在大流行前后均保持稳定。

适用人群与场景

  • 纳入商业保险或Medicare Advantage计划中持续参保的OUD患者,由提供办公室OUD照护的临床医生治疗。
  • 数据来源为OptumLabs数据仓库的去标识化行政索赔数据,覆盖大流行前(2019年3月14日至2020年3月13日)和大流行期(2020年3月14日至2021年3月13日)。

研究设计与关键结果

  • 研究类型为队列研究,纳入11801例患者(平均[SD]年龄53.9[15.7]岁;男性5902例[50.0%]),由1768名临床医生治疗。
  • 临床医生按远程医疗使用比例分为低、中、高三组;高使用组大流行期间平均69.5%(18.6%)的办公室访视以虚拟方式进行,低使用组为2.1%(2.5%)。
  • 主要终点:比较高 vs 低远程医疗使用组,大流行前后MOUD启动的调整OR为1.00(95%CI 0.84-1.19),MOUD供应天数差异变化为-0.27天(95%CI -1.84至1.30),OUD相关临床事件调整OR为1.01(95%CI 0.73-1.24),均无差异变化。
  • 总OUD访视量(面对面加远程医疗)在高使用组从2.6次/患者发作变为2.7次/患者发作,低使用组从3.1次/患者发作变为3.3次/患者发作,均保持稳定。

证据类型、等级与局限

  • 证据类型:队列研究,基于行政索赔数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,远程医疗是面对面OUD照护的可比替代方案。
  • 作者指出,无证据表明远程医疗与OUD治疗可及性增加或质量改善相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Little is known about the potential implications of the rapid transition to telehealth during the COVID-19 pandemic for treatment of opioid use disorder (OUD).

OBJECTIVE: To examine the association between telemedicine adoption during the COVID-19 pandemic and indicators of OUD treatment quality.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed deidentified administrative claims data from OptumLabs Data Warehouse. Claims for telemedicine visits were included for both the prepandemic period (March 14, 2019, to March 13, 2020) and pandemic period (March 14, 2020, to March 13, 2021). Patients with OUD and continuous enrollment in either commercial insurance or Medicare Advantage plans were included. Clinicians who provided office-based OUD care were included and categorized into low, medium, or high telemedicine use groups. Patients were attributed to the clinician (and corresponding telemedicine use group) from whom they received a plurality of OUD visits.

MAIN OUTCOMES AND MEASURES: The 4 outcomes were all outpatient visits, OUD visits (in person vs telemedicine) within 90 days of an index visit, medications for OUD (MOUD) prescribing, and OUD-related clinical events (including drug overdose, inpatient detoxification and rehabilitation center stay, or injection drug use-related infections).

RESULTS: The analysis included 11 801 patients (mean [SD] age, 53.9 [15.7] years; 5902 males [50.0%]) who were treated by 1768 clinicians. Clinicians with low vs high telemedicine use conducted a mean (SD) of 2.1% (2.5%) vs 69.5% (18.6%) of their office visits virtually in the pandemic period. While telemedicine use for OUD increased significantly from the prepandemic to pandemic periods, total OUD visit volume (in person plus telemedicine) per patient episode remained stable among both high (2.6 to 2.7 visits per patient episode) and low (3.1 to 3.3 visits per patient episode) telemedicine use groups. In adjusted analyses comparing the prepandemic with pandemic periods, there was no differential change in MOUD initiation (adjusted odds ratio [OR], 1.00; 95% CI, 0.84-1.19), MOUD days' supply (differential change in days' supply, -0.27; 95% CI, -1.84 to 1.30), or OUD-related clinical events (adjusted OR, 1.01; 95% CI, 0.73-1.24) among patients who were treated by clinicians in low vs high telemedicine use groups.

CONCLUSIONS AND RELEVANCE: Results of this study revealed that clinical outcomes were similar among patients who were treated by clinicians with high and low telemedicine use during the COVID-19 pandemic, suggesting that telemedicine is a comparable alternative to in-person OUD care. There was no evidence that telemedicine was associated with increased access to or improved quality of OUD treatment.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Hailu R, Mehrotra A, Huskamp HA, et al. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. JAMA Netw Open. 2023. PMID: 36692880. doi:10.1001/jamanetworkopen.2022.52381

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。